Management of DRESS Syndrome
Immediately discontinue the suspected culprit drug and initiate systemic corticosteroids as first-line therapy, with severity-based dosing guided by the extent of organ involvement. 1
Acute Phase Management
Initial Steps
- Withdraw all potentially causative medications immediately upon suspicion of DRESS, as early drug cessation is critical to preventing progression and reducing mortality 1, 2
- Identify the culprit drug through careful medication history, focusing on drugs started 2-8 weeks prior to symptom onset (common offenders include allopurinol, lamotrigine, vancomycin, and anticonvulsants) 3
Baseline Diagnostic Workup
The international consensus recommends a comprehensive initial evaluation including: 1
- Complete blood count with differential (looking for eosinophilia >1000/μL or >10%)
- Comprehensive metabolic panel with liver and kidney function tests
- Skin biopsy for histopathologic confirmation
- Viral serologies (EBV, HHV-6, CMV) to assess for reactivation
- Chest imaging if pulmonary symptoms present
- Cardiac evaluation if myocarditis suspected
Severity Assessment and Treatment Algorithm
Mild DRESS (no significant organ involvement): 1
- Supportive care with close monitoring
- Topical corticosteroids for skin manifestations
- Consider low-dose oral corticosteroids (0.5-1 mg/kg/day prednisone equivalent)
Moderate DRESS (limited organ involvement without life-threatening features): 1, 2
- Systemic corticosteroids: prednisone 0.5-1 mg/kg/day orally
- Slow taper over 6-12 weeks to prevent relapse (which occurs in approximately 12% of cases) 4
- Monitor for viral reactivation during steroid therapy
Severe DRESS (extensive organ damage, liver transaminases >5x ULN, renal dysfunction, or multi-organ involvement): 1, 2
- High-dose systemic corticosteroids: methylprednisolone 1-2 mg/kg/day IV or prednisone equivalent
- Prolonged taper over 3-6 months
- Consider adjunctive therapies if inadequate response within 3-5 days
Alternative and Adjunctive Therapies
Cyclosporine
For steroid-resistant, steroid-dependent, or contraindicated cases, cyclosporine represents an effective alternative with rapid symptom resolution. 5
- Dosing: 3-5 mg/kg/day divided twice daily
- Demonstrated 89% resolution rate with mean treatment duration of 5.26 days in a cohort study 5
- Particularly valuable in patients unable to sustain prolonged immunosuppression 5
- Relapse rate of 16% reported, lower than some steroid regimens 5
Other Second-Line Options
When first-line therapies fail: 6, 2, 7
- Intravenous immunoglobulin (IVIG): 2 g/kg divided over 3-5 days for refractory cases
- Plasmapheresis: Reserved for life-threatening cases with severe organ dysfunction 8
- N-acetylcysteine: May provide benefit in cases with significant hepatotoxicity 7
- Biologics and targeted therapies: Emerging options for refractory disease, though evidence remains limited 6
Critical Management Pitfalls
Viral Reactivation
- Human herpesvirus (especially HHV-6) reactivation occurs frequently during DRESS and can complicate the clinical picture 4
- Monitor viral titers during treatment, particularly in patients on high-dose corticosteroids
- Reactivation may trigger DRESS relapse and confound severity assessment 4
Premature Steroid Tapering
- Rapid taper increases relapse risk significantly 4, 2
- Maintain therapeutic doses until clinical and laboratory parameters normalize
- Taper should extend over months, not weeks, for moderate to severe cases 1, 2
Delayed Recognition
- DRESS carries 6.9% mortality when not promptly recognized and treated 3
- The syndrome affects 99.67% of patients as a serious adverse reaction requiring hospitalization 3
Post-Acute Phase Management
Follow-Up Monitoring
Continue surveillance for at least 6-12 months after resolution due to risks of relapse, autoimmune sequelae, and late complications. 1, 2
- Monitor for emergent autoimmunity (thyroiditis, type 1 diabetes, lupus-like syndromes) 9
- Serial laboratory testing every 2-4 weeks initially, then monthly
- Screen for viral reactivation if symptoms recur
Allergological Workup
Defer patch testing and delayed intradermal testing until at least 6 months after complete resolution and at least 4 weeks after discontinuing systemic corticosteroids (>10 mg prednisone equivalent). 4
- Patch testing shows 64% sensitivity for DRESS, the highest among severe cutaneous adverse reactions 4
- Testing before 6 months carries risk of DRESS relapse and viral reactivation 4
- Never rechallenge with the culprit drug, even if skin testing is negative, due to imperfect negative predictive value and risk of severe recurrence 4
- Delayed intradermal testing may be more sensitive than patch testing for certain drugs (antibiotics, anticonvulsants) 4